Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia

Schizophrenia Research

Volumn 108, Issue 1-3, 2009, Pages 134-142

  Polymeropoulos, Mihael H ^a   Licamele, Louis ^a,b   Volpi, Simona ^a   Mack, Kendra ^a   Mitkus, Shruti N ^a   Carstea, Eugene D ^a   Getoor, Lise ^b   Thompson, Andrew ^a   Lavedan, Christian ^a  

^a Vanda Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Antipsychotic action; Gene expression; Lipid homeostasis; Pathogenesis

Indexed keywords

ANTIDEPRESSANT AGENT; ANTILIPEMIC AGENT; ARIPIPRAZOLE; CHLORPROMAZINE; CHOLESTEROL; CLOMIFENE; CLOZAPINE; FATTY ACID; FLUPHENAZINE; HALOPERIDOL; ILOPERIDONE; LOXAPINE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PROMAZINE; QUETIAPINE; RALOXIFENE; RISPERIDONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; THIORIDAZINE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; ZIPRASIDONE;

ARTICLE; BIOSYNTHESIS; CELL LINE; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HOMEOSTASIS; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CELL LINE, TRANSFORMED; CHOLESTEROL; EPITHELIAL CELLS; FATTY ACIDS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MICROARRAY ANALYSIS; RECEPTORS, ESTROGEN; RETINA; STATISTICS, NONPARAMETRIC;

EID: 60249089094     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.11.025     Document Type: Article

References (64)

1. Baptista T., de Baptista E.A., Hernandez L., Altemus M., and Weiss S.R. Tamoxifen prevents sulpiride-induced weight gain in female rats. Pharmacol. Biochem. Behav. 57 (1997) 215-222
2. Carver J.D., Benford V.J., Han B., and Cantor A.B. The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects. Brain Res. Bull. 56 (2001) 79-85
3. Chen M.L., and Chen C.H. Microarray analysis of differentially expressed genes in rat frontal cortex under chronic risperidone treatment. Neuropsychopharmacology 30 (2005) 268-277
4. Cheng M.C., Liao D.L., Hsiung C.A., Chen C.Y., Liao Y.C., and Chen C.H. Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex. Int. J. Neuropsychopharmacol. 11 (2008) 207-216
5. Christensen O., and Christensen E. Fat consumption and schizophrenia. Acta Psychiatr. Scand. 78 (1988) 587-591
6. Dayspring T., Qu Y., and Keech C. Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia. Metabolism 55 (2006) 972-979
7. Duncan C.E., Chetcuti A.F., and Schofield P.R. Coregulation of genes in the mouse brain following treatment with clozapine, haloperidol, or olanzapine implicates altered potassium channel subunit expression in the mechanism of antipsychotic drug action. Psychiatr. Genet. 18 (2008) 226-239
8. Emsley R., Myburgh C., Oosthuizen P., and van Rensburg S.J. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry 159 (2002) 1596-1598
9. Emsley R., Rabinowitz J., and Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am. J. Psychiatry 163 (2006) 743-745
10. Fatemi S.H., Reutiman T.J., Folsom T.D., Bell C., Nos L., Fried P., Pearce D.A., Singh S., Siderovski D.P., Willard F.S., and Fukuda M. Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology 31 (2006) 1888-1899
11. Ferno J., Skrede S., Vik-Mo A.O., Havik B., and Steen V.M. Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci. 7 (2006) 69
12. Fornaro P., Calabria G., Corallo G., and Picotti G.B. Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis. Doc. Ophthalmol. 105 (2002) 41-49
13. Freedman R., Leonard S., Olincy A., Kaufmann C.A., Malaspina D., Cloninger C.R., Svrakic D., Faraone S.V., and Tsuang M.T. Evidence for the multigenic inheritance of schizophrenia. Am. J. Med. Genet. 105 (2001) 794-800
14. Gattaz W.F., Schmitt A., and Maras A. Increased platelet phospholipase A2 activity in schizophrenia. Schizophr. Res. 16 (1995) 1-6
15. Goff D.C., and Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 158 (2001) 1367-1377
16. Grigoriadis S., and Seeman M.V. The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can. J. Psychiatry 47 (2002) 437-442
17. Hanson D.R., and Gottesman I.I. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med. Genet. 6 (2005) 7
18. Harrop C., and Trower P. Why does schizophrenia develop at late adolescence?. Clin. Psychol. Rev. 21 (2001) 241-265
19. Hibbeln J.R. Fish consumption and major depression. Lancet 351 (1998) 1213
20. Horrobin D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr. Res. 30 (1998) 193-208
21. Horrobin D.F., Manku M.S., Hillman H., Iain A., and Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry 30 (1991) 795-805
22. Hulbert A.J. Membrane fatty acids as pacemakers of animal metabolism. Lipids 42 (2007) 811-819
23. Kaddurah-Daouk R., McEvoy J., Baillie R.A., Lee D., Yao J.K., Doraiswamy P.M., and Krishnan K.R. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol. Psychiatry 12 (2007) 934-945
24. Komoroski R.A., Pearce J.M., Griffin W.S., Mrak R.E., Omori M., and Karson C.N. Phospholipid abnormalities in postmortem schizophrenic brains detected by 31P nuclear magnetic resonance spectroscopy: a preliminary study. Psychiatry Res. 106 (2001) 171-180
25. Kulkarni J., Garland K.A., Scaffidi A., Headey B., Anderson R., de Castella A., Fitzgerald P., and Davis S.R. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 31 (2006) 543-547
26. Kulkarni J., Gurvich C., Gilbert H., Mehmedbegovic F., Mu L., Marston N., Gavrilidis E., and de Castella A. Hormone modulation: a novel therapeutic approach for women with severe mental illness. Aust. N. Z. J. Psychiatry 42 (2008) 83-88
27. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., Lerner J., Brunet J.P., Subramanian A., Ross K.N., Reich M., Hieronymus H., Wei G., Armstrong S.A., Haggarty S.J., Clemons P.A., Wei R., Carr S.A., Lander E.S., and Golub T.R. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313 (2006) 1929-1935
28. Lavedan C., Volpi S., Polymeropoulos M.H., and Wolfgang C.D. Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial. Pharmacogenomics 9 (2008) 289-301
29. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
30. Lomax J. Get ready to GO! A biologist's guide to the Gene Ontology. Brief Bioinform. 6 (2005) 298-304
31. Lum P.Y., Armour C.D., Stepaniants S.B., Cavet G., Wolf M.K., Butler J.S., Hinshaw J.C., Garnier P., Prestwich G.D., Leonardson A., Garrett-Engele P., Rush C.M., Bard M., Schimmack G., Phillips J.W., Roberts C.J., and Shoemaker D.D. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116 (2004) 121-137
32. Maida M.E., Hurley S.D., Daeschner J.A., Moore A.H., and O'Banion M.K. Cytosolic prostaglandin E2 synthase (cPGES) expression is decreased in discrete cortical regions in psychiatric disease. Brain Res. 1103 (2006) 164-172
33. McNamara R.K., Jandacek R., Rider T., Tso P., Hahn C.G., Richtand N.M., and Stanford K.E. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications. Schizophr. Res. 91 (2007) 37-50
34. Nasrallah H.A. Neurodevelopmental pathogenesis of schizophrenia. Psychiatr. Clin. North Am. 16 (1993) 269-280
35. Newcomer J.W. Antipsychotic medications: metabolic and cardiovascular risk. J. Clin. Psychiatry 68 Suppl 4 (2007) 8-13
36. Newman J.C., and Weiner A.M. L2L: a simple tool for discovering the hidden significance in microarray expression data. Genome Biol. 6 (2005) R81
37. Ntambi J.M. Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. J. Lipid Res. 40 (1999) 1549-1558
38. Peet M. Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results. Prostaglandins Leukot. Essent. Fat. Acids 69 (2003) 477-485
39. Power R.F., Mani S.K., Codina J., Conneely O.M., and O'Malley B.W. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 254 (1991) 1636-1639
40. Puri B.K., Richardson A.J., Horrobin D.F., Easton T., Saeed N., Oatridge A., Hajnal J.V., and Bydder G.M. Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes. Int. J. Clin. Pract. 54 (2000) 57-63
41. Raedler T.J., Bymaster F.P., Tandon R., Copolov D., and Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol. Psychiatry 12 (2007) 232-246
42. Reddy R.D., Keshavan M.S., and Yao J.K. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr. Bull. 30 (2004) 901-911
43. Reis L.C., and Hibbeln J.R. Cultural symbolism of fish and the psychotropic properties of omega-3 fatty acids. Prostaglandins Leukot. Essent. Fat. Acids 75 (2006) 227-236
44. Richardson A.J. The role of omega 3 fatty acids in behaviour, cognition and mood. Scand. J. Nutr. 47 (2003) 92-98
45. Richardson A.J., Easton T., Gruzelier J.H., and Puri B.K. Laterality changes accompanying symptom remission in schizophrenia following treatment with eicosapentaenoic acid. Int. J. Psychophysiol. 34 (1999) 333-339
46. Rudin D.O. The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. Biol. Psychiatry 16 (1981) 837-850
47. Rudin D.O. The dominant diseases of modernized societies as omega-3 essential fatty acid deficiency syndrome: substrate beriberi. Med. Hypotheses 8 (1982) 17-47
48. Ryan M.C., Collins P., and Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 160 (2003) 284-289
49. Schmitt A., Wilczek K., Blennow K., Maras A., Jatzko A., Petroianu G., Braus D.F., and Gattaz W.F. Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol. Psychiatry 56 (2004) 41-45
50. Sivrioglu E.Y., Kirli S., Sipahioglu D., Gursoy B., and Sarandol E. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Prog. Neuro-psychopharmacol. Biol. Psychiatry 31 (2007) 1493-1499
51. Sleeman M.W., Garcia K., Liu R., Murray J.D., Malinova L., Moncrieffe M., Yancopoulos G.D., and Wiegand S.J. Ciliary neurotrophic factor improves diabetic parameters and hepatic steatosis and increases basal metabolic rate in db/db mice. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14297-14302
52. Smesny S., Kinder D., Willhardt I., Rosburg T., Lasch J., Berger G., and Sauer H. Increased calcium-independent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia. Biol. Psychiatry 57 (2005) 399-405
53. Thakore J.H., Mann J.N., Vlahos I., Martin A., and Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int. J. Obes. Relat. Metab. Disord. 26 (2002) 137-141
54. Thomas E.A., George R.C., Danielson P.E., Nelson P.A., Warren A.J., Lo D., and Sutcliffe J.G. Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins. Mol. Psychiatry 8 (2003) 983-993 950
55. Toda M., and Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all. Curr. Psychiatry Rep. 9 (2007) 329-336
56. Tsuang M.T., Bar J.L., Stone W.S., and Faraone S.V. Gene-environment interactions in mental disorders. World Psychiatry 3 (2004) 73-83
57. Van Os J., and Sham P. The epidemiology of schizophrenia. In: Murray R.M., Jones P.B., Susser E., Van Os J., and Cannon M. (Eds) (2003), Cambridge University Press 235-254 Ref Type: Serial (Book, Monograph)
58. Vik-Mo A.O., Birkenaes A.B., Ferno J., Jonsdottir H., Andreassen O.A., and Steen V.M. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int. J. Neuropsychopharmacol. (2008) 1-6
59. Wang H.H., Afdhal N.H., and Wang D.Q. Overexpression of estrogen receptor alpha increases hepatic cholesterogenesis, leading to biliary hypersecretion in mice. J. Lipid Res. 47 (2006) 778-786
60. Weickert C.S., Miranda-Angulo A.L., Wong J., Perlman W.R., Ward S.E., Radhakrishna V., Straub R.E., Weinberger D.R., and Kleinman J.E. Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum. Mol. Genet. 17 (2008) 2293-2309
61. Yao J.K., Leonard S., and Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 42 (2000) 7-17
62. Yao J.K., Magan S., Sonel A.F., Gurklis J.A., Sanders R., and Reddy R.D. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Prostaglandins Leukot. Essent. Fat. Acids 71 (2004) 171-176
63. Yildiz A., Guleryuz S., Ankerst D.P., Ongur D., and Renshaw P.F. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch. Gen. Psychiatry 65 (2008) 255-263
64. Zarate Jr. C.A., Singh J.B., Carlson P.J., Quiroz J., Jolkovsky L., Luckenbaugh D.A., and Manji H.K. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord. 9 (2007) 561-570